Sellar & Parasellar Targets Beyond Pituitary Adenoma

1.A tumor defined by where it sits

Craniopharyngiomas are histologically benign but are adherent to the optic apparatus, pituitary stalk, and hypothalamus, and are characteristically part-solid, part-cystic. Management balances maximal safe resection against hypothalamic and visual morbidity; deliberate subtotal resection followed by radiation is often preferable to injurious radical surgery. Radiosurgery suits a small, predominantly solid residual or recurrent nodule for which the plan can meet optic constraints. Larger, cystic, or perioptic disease is generally better suited to fractionated stereotactic radiotherapy or proton therapy. Reported single-session margin doses cluster between 11 and 15 Gy, and the ISRS pediatric guideline meta-analysis found pooled local control of 89% at an average dose of 13.1 Gy. Durability is more modest than for other benign sellar targets: pooled progression-free survival is roughly 81% at 3 years and 69% at 5 years, and large Gamma Knife series report 5- and 10-year PFS near 60% and 45%. When conventional fractionation is chosen instead, the standard dose is 54 Gy in 30 fractions, and doses below about 54 Gy are associated with worse local control. Subtype also drives systemic options: adamantinomatous craniopharyngioma is pediatric-predominant and almost always carries a CTNNB1 mutation, while the papillary subtype is adult-predominant and typically harbors BRAF V600E, for which BRAF-MEK inhibition with vemurafenib and cobimetinib produces high response rates and can be given before surgery or radiation to reduce the extent of either. Molecular testing therefore belongs in the workup rather than as an afterthought.

2.The cyst problem

A cystic component predicts lower progression-free survival, and cysts can enlarge during or after radiation, sometimes acutely threatening vision. Practical management combines cyst drainage (an Ommaya/cysto-ventricular catheter) with focused radiation of the solid component, and monitors cyst dynamics closely after treatment. Large lesions abutting the optics are generally better served by fractionated stereotactic radiotherapy or proton therapy than single-fraction SRS. Two distinct intracavitary approaches exist for predominantly cystic disease at selected centers. Intracavitary brachytherapy instills a beta-emitting isotope, usually phosphorus-32 or yttrium-90, into the cyst. Intracystic chemotherapy instills bleomycin or interferon-alpha, with reported response rates of 62 to 100% and interferon generally better tolerated. Both risk visual deterioration, cranial neuropathy, and new endocrine deficits.

3.When the target hugs the optic apparatus

The defining constraint of the sellar/parasellar region is the optic apparatus. Distance is a useful preplanning clue, but the actual dose-volume relationship decides: if a single-fraction tumor dose cannot be delivered while meeting the optic pathway constraint, the solution is hypofractionation or conventionally fractionated radiotherapy. Spreading dose over 3–5 fractions exploits the optic apparatus's fractionation sensitivity; commonly used regimens include 21 Gy/3 fractions and 25 Gy/5 fractions, selected according to histology, target volume, prior treatment, and institutional protocol.

4.The numbers that drive the plan

Radiation-induced optic neuropathy is the feared, largely untreatable complication, so constraints are conservative. Single-fraction tolerance was historically set at 8 Gy, and later single-institution series reported very low risk with optic maximum doses up to 12 Gy in previously unirradiated patients. HyTEC pooled these data and recommends an optic apparatus maximum dose of no more than 10 Gy in 1 fraction, 20 Gy in 3 fractions, and 25 Gy in 5 fractions without prior radiotherapy, each corresponding to roughly a 1% risk of optic neuropathy; a Stanford series of 262 patients independently confirmed under 1% toxicity at a single-fraction optic maximum of 10 Gy. Prior irradiation lowers tolerance, demanding tighter limits. These are point-maximum constraints applied to a carefully contoured optic apparatus.

5.Where SRS does and does not belong

• Rathke cleft cyst: a benign cystic remnant managed by drainage/fenestration when symptomatic, not a radiosurgical target.
• Optic pathway / hypothalamic glioma (largely pediatric): managed with chemotherapy and, when radiation is needed, fractionated or proton therapy: single-fraction SRS is avoided given the optic involvement and late-effect concerns in children.
• Parasellar meningioma and pituitary adenoma: covered on the meningioma and pituitary pages; the same perioptic fractionation logic applies when they abut the optic apparatus or cavernous sinus.